medigraphic.com
ISSN 1561-302X (Print)

2015, Number 1

<< Back Next >>

Rev cubana med 2015; 54 (1)

Renal denervation, a milestone in the treatment of hypertension

Arredondo BA, Pons VR

Language: Spanish
References: 30
Page: 67-73
PDF size: 105.69 Kb.


ABSTRACT

Hypertension is a significant global threat and a major risk factor for cardiovascular disease. A literature review was conducted in PubMed, Embase, Medline, and Scielo databases on therapeutic renal denervation, until mid-2014, as a promising version of a historical treatment whereby kidney sympathetic activation is reduced in resistant hypertension and in other stages of vascular disease, including heart failure. This review focused on contemporary evidence on the usefulness of renal denervation; its current status and the various devices were reviewed (EnligHTN™ [St Jude Medical, MN, USA], Vessix™ Vascular V2 [Boston Scientific, MA, USA], OneShot™ [Covidien, CA, USA] y PARADISE® [ReCor Medical, CA, USA]). Treatment indications were considered and the various problems still unresolved were analyzed (no effect in reducing morbidity or mortality has been shown. The main cause of refractory hypertension is patient noncompliance; and the benefit of renal denervation may be for the best adherence to therapy. Ambulatory reducing BP is lower than in consultation), since the need to be resolved before renal denervation is considered a therapy of choice.


REFERENCES

  1. Sathananthan J, Watson T, Whitbourn RJ, Stewart JT, Doughty RN, Ormiston R, et al. Renal Sympathetic Denervation: Indications, Contemporary Devices and Future Directions. Interv Cardiol. 2014;6(1):57-69.

  2. Williams B. The year in hypertension. J Am Coll Cardiol. 2009;55:65-73.

  3. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-8.

  4. Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013;15:134-6.

  5. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.

  6. Danaei G, Finucane MM, Lin JK. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377:568-77.

  7. Mancia G, Fagard R, Narkiewicz K. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219.

  8. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-80.

  9. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012;125:1594-6.

  10. Daugherty SL, Powers JD, Magid DJ. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635-42.

  11. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report. Heart. 2012;99(21):1579-87.

  12. Bunte MC, Infante de Oliveira E, Shishehbor MH. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Inter. 2013;6:1-9.

  13. Ewen S, Ukena C, Bohm M, Mahfoud F. Percutaneous renal denervation: new treatment option for resistant hypertension and more? Heart. 2013;99:1129-34.

  14. Hering D, Walton A, Krum H, Lambert G, Esler M, Schlaich M. Renal artery ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. Int J Cardiol. 2012;159(2): e35-e36.

  15. Geisler BP, Egan BM, Cohen JT. Cost–effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60:1271-7.

  16. Hering D, Lambert E, Marusic P. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-64.

  17. Davis MI, Filion KB, Zhang D. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:231-41.

  18. Ukena C, Mahfoud F, Spies A. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol. 2013;167:2846-51.

  19. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75- 197.

  20. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1:403-8.

  21. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol. 2010;105:570-6.

  22. Krum H, Schlaich M, Whitbourn R. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.

  23. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976-82.

  24. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–1201.

  25. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.

  26. Bakris GL. Interventional cardiology: indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013;10:434-6.

  27. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903-9.

  28. Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:231-41.

  29. Hering D, Mahfoud F, Walton AS. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-7.

  30. Hering D, Lambert E, Marusic P. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-64.




2020     |     www.medigraphic.com